Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Brendan, Frett"'
Autor:
Zachary J. Waldrip, Baku Acharya, Daniel Armstrong, Maha Hanafi, Randall R. Rainwater, Sharon Amole, Madeline Fulmer, Ana Clara Azevedo-Pouly, Alaina Burns, Lyle Burdine, Brendan Frett, Marie Schluterman Burdine
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract DNA-dependent protein kinase catalytic subunit (DNA-PKcs) plays a vital role in DNA damage repair and lymphocyte function, presenting a significant target in cancer and immune diseases. Current DNA-PKcs inhibitors are undergoing Phase I/II t
Externí odkaz:
https://doaj.org/article/b870b333c6794adaa74c1377d301427d
Autor:
Henry Anthony Palfrey, Samaneh Goorani, Amod Sharma, Baku Acharya, Brendan Frett, John D. Imig
Publikováno v:
Journal of Clinical and Translational Science, Vol 8, Pp 166-166 (2024)
OBJECTIVES/GOALS: Renal fibrosis is a critical pathophysiological event in chronic kidney diseases. Our goal is to determine the ability of dual-inhibitor of transforming growth factor beta receptor 1 (TGFα²R1) and mitogen-activated protein kinase
Externí odkaz:
https://doaj.org/article/296d9a77d5564ee4aca3cf447f629771
Autor:
Marialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, Brendan Frett, Nicholas McConnell, Lingtian Zhang, Annalisa Brescia, Giorgia Federico, Lingzhi Zhang, Paolo Salerno, Massimo Santoro, Hong-yu Li, Francesca Carlomagno
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract We have recently described Pz-1, a benzimidazole-based type-2 RET and VEGFR2 inhibitor. Based on a kinome scan, here we show that Pz-1 is also a potent (IC50
Externí odkaz:
https://doaj.org/article/eab71864d5a542ee8748ff9464f7f61c
Publikováno v:
Journal of Clinical and Translational Science, Vol 7, Pp 131-131 (2023)
OBJECTIVES/GOALS: T develop a novel PROTAC to deplete BRK to inhibit tumorigenesis and metastasis, which is unattainable by using tradition kinase inhibitors. METHODS/STUDY POPULATION: We will design, synthesize, and evaluate BRK-specific PROTACs to
Externí odkaz:
https://doaj.org/article/4f121c1fc97e4642bbf29fd989554bc4
Autor:
Baku, Acharya, Brendan, Frett
Publikováno v:
Expert Opinion on Therapeutic Patents. 32:1067-1077
Rearranged during transfection (RET) is a transmembrane receptor tyrosine kinase. Aberrations in RET signaling due to mutations, gene fusions, or overexpression can lead to carcinomas. Six inhibitors have been approved for the treatment of RET-driven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3887ce191797bb91fdc1f15eefe0e61
https://doi.org/10.1080/13543776.2022.2132851
https://doi.org/10.1080/13543776.2022.2132851
Autor:
Lingtian Zhang, Marialuisa Moccia, David C. Briggs, Jaideep B. Bharate, Naga Rajiv Lakkaniga, Phillip Knowles, Wei Yan, Phuc Tran, Anupreet Kharbanda, Xiuqi Wang, Yuet-Kin Leung, Brendan Frett, Massimo Santoro, Neil Q. McDonald, Francesca Carlomagno, Hong-yu Li
Publikováno v:
Journal of Medicinal Chemistry. 65:1536-1551
Mutations of the rearranged during transfection (RET) kinase are frequently reported in cancer, which make it as an attractive therapeutic target. Herein, we discovered a series of N-trisubstituted pyrimidine derivatives as potent inhibitors for both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5de99c59f8ad8a17aa62c446b5f5bf21
https://doi.org/10.1021/acs.jmedchem.1c01280
https://doi.org/10.1021/acs.jmedchem.1c01280
Publikováno v:
RSC Med Chem
FLT3 mutations are one of the most common genetic aberrations found in nearly 30% of acute myeloid leukemias (AML). The mutations are associated with poor prognosis despite advances in the understanding of the biological mechanisms of AML. Numerous s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a645a7e54c592451ec34aaafa966ac3a
https://doi.org/10.1039/d2md00067a
https://doi.org/10.1039/d2md00067a
Autor:
Debasmita Saha, Erica Lane Smith, Katie R. Ryan, Baku Acharya, Naga Rajiv Lakkaniga, Brendan Frett, Noemi Garcia Garcia
Publikováno v:
J Med Chem
REarranged during Transfection (RET) is a receptor tyrosine kinase essential for the normal development and maturation of a diverse range of tissues. Aberrant RET signaling in cancers, due to RET mutations, gene fusions, and over-expression, results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d900c6140bc51abc4a51602080b588a3
https://doi.org/10.1021/acs.jmedchem.0c02167
https://doi.org/10.1021/acs.jmedchem.0c02167
Autor:
Kennith Swafford, Baku Acharya, Ying-Zhi Xu, Thomas Raney, Mason McCrury, Debasmita Saha, Brendan Frett, Samantha Kendrick
Publikováno v:
Genes; Volume 13; Issue 7; Pages: 1144
The aggressive nature of the activated B cell such as (ABC) subtype of diffuse large B cell (DLBCL) is frequently associated with altered B cell Receptor (BCR) signaling through the activation of key components including the scaffolding protein, CARD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d687ee05240826ca62f314cf85591c5
Publikováno v:
ChemMedChem
A fragment-based drug discovery approach using a pyrazoloadenine fragment library was utilized to uncover new molecules that target the RET (REarranged during Transfection) oncoprotein, which is a driver oncoprotein in ~2% of non-small cell lung canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f3b737bf1a703978c6ecc177c789508
https://doi.org/10.1002/cmdc.202100013
https://doi.org/10.1002/cmdc.202100013